Artiva Biotherapeutics is preparing to unveil initial results from its unmodified, preserved natural killer (NK) cell therapy in patients with autoimmune disease. This allogeneic product, designed to overcome logistical and safety hurdles faced by CAR T–cell approaches, demonstrated promising activity in early B-cell lymphoma cohorts, with 60% of evaluable patients achieving objective responses and median duration of response exceeding six months. Investors will be watching closely as the company has scheduled data readouts at two major immunology conferences over the next quarter, potentially shifting market focus from oncology to the broader autoimmune opportunity.

Six research firms covering the company have established a consensus twelve-month price objective of $19.00 and collectively recommend a moderate buy stance. Within that group, one firm maintains a sell opinion, four have issued buy recommendations and one has elevated its rating to strong buy. Since mid-October, Jefferies upgraded its view to strong buy, HC Wainwright raised its target from $12.00 to $15.00, and Wedbush lifted its objective from $18.00 to $23.00. These revisions reflect growing confidence in Artiva’s ability to expand into autoimmune indications following encouraging lymphoma signals.

CEO Fred Aslan reduced his holdings by 6.7%, selling 25,500 shares at an average of $6.00 for gross proceeds of $153,000, leaving him with roughly 356,700 shares. Over the past 90 days, insiders collectively sold 35,062 shares valued at $193,670, representing 21.4% insider ownership. Meanwhile, several hedge funds have initiated or expanded positions: Ground Swell Capital and Prelude Capital Management each invested around $40,000 in the second and third quarters, Bank of America more than tripled its stake to 16,145 shares, and Bridgeway Capital added $53,000 worth of stock. This mix of sales by executives and fresh institutional inflows underscores a rotation toward long-term growth narratives tied to upcoming clinical catalysts.